Navigation Links
Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma
Date:5/27/2008

open to both treatment-naive and previously treated patients, ultimately enrolling a much larger treatment-naive population (78%). Patients were randomized at a one-to-one ratio to receive either Specifid or placebo following a standard course of Rituxan. The trial was conducted at 67 centers in the U.S.

Conference Call and Webcast

Favrille's management team will host a conference call today at 8:30 a.m. Eastern Time to discuss the information contained in this press release. A live audio webcast will be available on the Investor Relations section of the Company's web site at http://www.favrille.com . Alternatively, callers may participate in the conference call by dialing (866) 831-6267 or (617) 213-8857, passcode 99549869. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 20389415.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to continue its operations, conserve cash or recognize value on our assets and additional risks discussed in Favrille's filings with the Securiti
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Favrille Reports First Quarter 2008 Financial Results
2. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
3. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
4. Favrille Announces $21.1 Million Registered Direct Offering
5. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
6. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
7. Favrille to Present at BIO InvestorForum
8. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
9. Favrille CEO to Present at Bear Stearns Healthcare Conference
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Unraveling life’s mysteries can ... The Archer Family purchased a DNA test ... ended up with a lifetime of memories, sharing, and ... family members’ DNA genuinely brought the family closer together. ... deeper into genetic history and prior to taking the ...
(Date:7/10/2014)... Senior supply chain management executives from over ... challenges of “Reducing Cost, Lead Time, & Defects in ... Describing the partnership of the Bio Supply Management Alliance ... ( SCMI) of the University of San Diego ... Kroc Institute of Peace and Justice in San Diego, ...
(Date:7/10/2014)... 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the ... announced an agreement with Lineagen, Inc., to ... NextStep Dx PLUS.  Lineagen, focused on ... disorders, currently offers FirstStep Dx PLUS, ... used by healthcare providers as a first-line ...
(Date:7/10/2014)... help in the fight against terrorism with the creation ... explosives with the use of light and special glass ... Actuators B: Chemical , the researchers describe a novel ... as low as 6.3 ppm (parts per million). It ... , "Traditionally explosives detection has involved looking for metals ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Detecting trace amounts of explosives with light 2
... RIDGE, Tenn., Feb. 4, 2010 -- Four Oak Ridge ... will receive five-year research grants as part of the ... The $85 million program, funded under the American Recovery ... is designed to support exceptional researchers during the crucial ...
... , ... and HEALTHeCAREERS Network , leading employment communities for ... career sites recently recognized by recruiters and job seekers. , ... ) , The same audiences have chosen Hcareers for the ...
... ... Opportunities and Challenges of Maize Cultivation Under Dry Conditions , ... Bordeaux, France (Vocus) February 4, 2010 -- ... develop drought-tolerant crops, which will play a major role in sustainably increasing agricultural productivity, ...
Cached Biology Technology:4 ORNL researchers selected for Recovery Act early career funds 24 ORNL researchers selected for Recovery Act early career funds 3Industry Web Sites Continue to Win Online Award 2Industry Web Sites Continue to Win Online Award 3DuPont Leader: Drought-Tolerant Crops Developed Through Modern Breeding are Key to Sustainably Increasing Grain Production 2
(Date:7/10/2014)...  Pomerantz LLP has filed a class action ... "Company")(NYSE-MKT: PVCT) and certain of its officers.  The ... Middle District of Tennessee , ... consisting of all persons or entities who purchased ... 2013 and May 22, 2014, both dates inclusive ...
(Date:7/10/2014)... July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ... Mr. Gino Pereira was interviewed on July 1 ... Tampa Florida . Mr. Pereira discusses the company,s ... Harris and how the Wocket™ aims to replace a ... Cedric Harris tells Gino he has never ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new ... (DW). An Asian OEM has selected FPC1021 for a flagship ... August 2014.   FPC is proud to announce ... planned date for start of mass production in August 2014. ... 5M, for delivery in the first half of July. The ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... similar small molecules appear capable of protecting cells ... RELEVANCE: Parkinson,s disease is a neurodegenerative ... movements. There is currently no cure for the ... symptoms, not the disease,s cellular cause. Small ...
... London, New Delhi, Singapore and Washington DC (Dec 28, 2010) ... individual,s identify with political parties , according to an article ... the official journal of the Western Political Science Association (published ... most studied concepts in modern political science. Scholars have long ...
... during early development when future spinal cord cells growing in ... In the Dec. 6 issue of Nature Cell Biology ... team with colleagues at the University of California, Berkeley to ... spinal cord development, a discovery that opens new doors for ...
Cached Biology News:Small molecules found to protect cells in multiple models of Parkinson's disease 2Small molecules found to protect cells in multiple models of Parkinson's disease 31 step closer to closure 2
Non-Receptor Tyrosine Kinase Sampler Kit 10 mu g each...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
PKA Sampler Kit 10 mu g each...
Rabbit polyclonal to BCA1 ( Abpromise for all tested applications). Antigen: Generated using E.coli expressed mouse BCA1. Entrez GeneID: 10563 SWISS Protein ID: O43927...
Biology Products: